Equities

Tandem Diabetes Care Inc

Tandem Diabetes Care Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)30.61
  • Today's Change-0.131 / -0.42%
  • Shares traded589.77k
  • 1 Year change+60.76%
  • Beta1.3420
Data delayed at least 15 minutes, as of Nov 22 2024 19:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy6
Outperform10
Hold6
Sell1
Strong Sell0

Share price forecast in USD

The 20 analysts offering 12 month price targets for Tandem Diabetes Care Inc have a median target of 56.50, with a high estimate of 75.00 and a low estimate of 18.00. The median estimate represents a 83.80% increase from the last price of 30.74.
High144.0%75.00
Med83.8%56.50
Low-41.4%18.00

Earnings history & estimates in USD

On Nov 06, 2024, Tandem Diabetes Care Inc reported 3rd quarter 2024 losses of -0.35 per share. This result exceeded the -0.41 consensus loss of the 19 analysts covering the company and exceeded last year's 3rd quarter results by 7.89%.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate-14.64%
Tandem Diabetes Care Inc reported annual 2023 losses of -1.60 per share on Feb 21, 2024.
Average growth rate-21.09%
More ▼

Revenue history & estimates in USD

Tandem Diabetes Care, Inc. had 3rd quarter 2024 revenues of 243.97m. This bettered the 223.66m consensus of the 19 analysts covering the company. This was 42.34% above the prior year's 3rd quarter results.
Average growth rate+7.28%
Tandem Diabetes Care, Inc. had revenues for the full year 2023 of 747.72m. This was 6.68% below the prior year's results.
Average growth rate+21.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.